Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
18 June, 2018 07:32 IST
Sun Pharma receives USFDA EIR for Halol facility
Source: IRIS | 12 Jun, 2018, 05.22PM
Comments  |  Post Comment

Sun Pharmaceutical Industries today announced that it has received the Establishment Inspection Report (EIR) from the US FDA for the inspection conducted at its Halol facility (Gujarat, India) during the period February 12-23, 2018. The agency concluded that the inspection is now closed and the issues contained in the Warning Letter issued in December 2015 have been addressed.

Dilip Shanghvi, Managing Director, Sun Pharma (Q,N,C,F)* said, ''This is an important development for Sun Pharma. We remain committed to following the highest levels of quality and 24x7 cGMP compliance at all our manufacturing facilities globally.'' 

Shares of the company gained Rs 5.5, or 1.03%, to settle at Rs 540.50. The total volume of shares traded was 507,842 at the BSE (Tuesday).



Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Related Articles
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer